Ert Pompe denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for ERT in Pompe Disease

Blue Cross Blue Shield plans consistently require prior authorization (PA) for enzyme replacement therapy (ERT) in Pompe disease. ERT is an expensive specialty biologic administered on an ongoing infusion schedule, and Pompe disease is a rare condition that requires specialist-level diagnosis and management. BCBS uses PA to verify: that the Pompe disease diagnosis is definitively established through appropriate testing, that the prescriber has relevant specialty expertise, and that the clinical presentation falls within the coverage criteria in its published medical policy. A PA denial — or a claim denied because PA was not obtained — is appealable.

## Why This Denial Is Appealable

If the PA was denied because of incomplete documentation, the appeal corrects that by supplying the missing evidence. If the PA was denied on clinical grounds — meaning BCBS concluded the patient does not meet coverage criteria — the appeal challenges that finding directly, mapping every criterion to the evidence in the chart and the FDA-approved prescribing label.

## Federal Appeal Framework

• Internal appeal: Submit within the deadline on the denial letter. For an active patient with progressive Pompe disease, document clinical urgency and request expedited review — BCBS must respond within 72 hours to expedited appeals and 30 days to standard appeals.
• External review (ACA §2719): After a final internal denial, request independent external review. The IRO evaluates whether the PA denial is consistent with generally accepted medical standards for Pompe disease. The four-month external-review request window begins from the date of final internal denial.
• Expedited external review: Available when standard timelines would seriously jeopardize health. Pompe disease is a progressive, potentially life-threatening condition; document the clinical stakes explicitly.
• ERISA §503 (employer plans): You are entitled to the specific clinical criteria applied, the reviewer's credentials and specialty, and all documents used in the coverage determination. Request the complete claims file.

## Documentation to Gather

• Genetic and enzymatic diagnosis confirmation: GAA gene mutation analysis and/or acid alpha-glucosidase enzyme activity assay from an appropriate laboratory, interpreted by a qualified specialist — this is the non-negotiable foundation of any Pompe ERT PA appeal.
• Clinical severity and functional status documentation: Dated assessments of respiratory function, motor function, and overall functional status. BCBS coverage criteria often specify functional thresholds; ensure the chart contains objective, recent measurements.
• Disease progression records: Clinical notes documenting the course of the disease over time, establishing both diagnosis certainty and the urgency of treatment.
• Specialist prescriber credentials: Confirmation that the ordering physician is a metabolic disease specialist, neurologist, or other specialty the BCBS policy designates.
• Medical necessity letter: A detailed, criterion-by-criterion letter from the treating specialist. The letter should reference the FDA-approved prescribing label and applicable specialist-society guidelines (by organization name), and address every element of the BCBS PA criteria explicitly.

## Criteria-Mapping Structure

Obtain the current BCBS medical policy for ERT in Pompe disease and list every PA criterion. Build a table:

| PA Criterion (from BCBS policy) | Satisfying Chart Evidence | |---|---| | Confirmed Pompe disease (genetic or enzymatic basis) | [Lab report, date, interpreting clinician] | | Specialist prescriber requirement | [Ordering physician's specialty and credentials] | | Functional/clinical status (per policy) | [Objective test results, dated] | | FDA label indication alignment | [Prescribing label excerpt] | | Prior treatment history (if required by policy) | [Treatment timeline with dates and clinical outcomes] |

Organize your appeal with this table as the centerpiece, with numbered exhibits for each document referenced. PA appeals for rare-disease ERT that present a complete, criterion-mapped record are substantially more likely to succeed at the first internal level.